Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: A phase I study

Journal of Clinical Oncology

Volumn 15, Issue 3, 1997, Pages 901-907

  Safran, H ^a   King, T P ^a   Choy, H ^a   Hesketh, P J ^a   Wolf, B ^a   Altenhein, E ^a   Sikov, W ^a   Rosmarin, A ^a   Akerley, W ^a   Radie Keane, K ^a   Cicchetti, G ^a   Lopez, F ^a   Bland, K ^a   Wanebo, H J ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PROTEIN P53;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CACHEXIA; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG HYPERSENSITIVITY; HUMAN; IMMUNE DEFICIENCY; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM ALLOWABLE CONCENTRATION; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; THROMBOSIS; TUMOR SUPPRESSOR GENE;

EID: 0031044606     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.3.901     Document Type: Article

References (40)

1. Thomas RMP: Radiotherapy for carcinoma of the pancreas. Semin Oncol 23:213-219, 1996
2. Moertel C, Childs D, Reiemeir R, et al: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1:865-867, 1969
3. Hoffman JP, Weese JL, Lipsitz S, et al: Preoperative chemoradiation for patients with resectable pancreatic adenocarcinoma: An Eastern Cooperative Oncology Group (ECOG) phase II study. Proc Am Soc Clin Oncol 14:201, 1995 (abstr 482)
4. Minsky BD: The role of radiation therapy in gastric cancer. Semin Oncol 23:390-396, 1996
5. Geard CR, Jones JM, Schiff PB: Taxol and radiation. J Natl Cancer Inst 15:89-94, 1993
6. Tishler R, Schiff P, Geard C, et al: Taxol: A novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22:613-617, 1992
7. Liebmann J, Cook JA, Fisher J, et al: In vitro studies of taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 86:441-446, 1994
8. Choy H, Akerley W, Safran H, et al: Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 12:2682-2686, 1994
9. Choy H, Akerley W, Safran H, et al: Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 15:371, 1996 (abstr 1098)
10. Hartwell LH, Kastan MB: Cell cycle control and cancer. Science 266:1821-1828, 1994
11. Chang F, Syrjanen S, Syrjanen K: Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13:1009-1022, 1995
12. Lowe SW, Ruley HE, Jacks T: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993
13. Lowe SW, Bodis S, McClatchey A, et al: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994
14. Dohner H, Fischer K, Bentz M, et al: p53 gene deletion predicts for poor survival and nonresponse to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580-1589, 1995
15. Wattel E, Preudhomme C, Hecquet B, et al: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148-3157, 1994
16. Lenz HJ, Danenberg KD, Leichman K, et al: p53 status and thymidylate synthase levels are predictors of chemotherapy efficacy in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 15:216, 1996 (abstr 504)
17. Kawasaki M, Nakanishi Y, Kuwano K, et al: The utility of p53 immunostaining for the transbronchial biopsy specimens of lung cancer: p53 overexpression may predict poor prognosis and chemoresistance in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 15:94, 1996 (abstr 40)
18. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 253:49-53, 1991
19. Nigro JM, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumor types. Nature 342:705-708, 1989
20. Tahara E, Semba S, Tahara H: Molecular observations in gastric cancer. Semin Oncol 23:307-315, 1996
21. Uchino S, Noguchi M, Ochiai A: p53 mutation in gastric cancer: A genetic model for carcinogenesis is common to gastric and colorectal cancer. Int J Cancer 54:759-764, 1993
22. Fisher DE, Bodis S, Lowe S, et al: Restoration of apoptosis in p53 deficient tumor cells. Proc Am Soc Hematol 84:111, 1994 (abstr 430)
23. Wahl AF, Donaldson KL, Fairchild C, et al: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 2:72-79, 1996
24. Safran H, King T, Choy H, et al: p53 mutations do not predict response to paclitaxel/radiation for non-small cell lung cancer. Cancer 78:1209-1216, 1996
25. Mohiuddin M, Rosato F, Schuricht A, et al: Carcinoma of the pancreas - the Jefferson experience. Eur J Surg Oncol 20:13-20, 1994
26. Vezeridis MP, Wanebo HJ: Pancreatic cancer in 1994: Diagnosis and treatment. RI Med 77:115-118, 1994
27. Gunderson LL, Sosin H: Adenocarcinoma of the stomach: Areas of failure in a reoperation series (second or symptomatic looks): Clinicopathologic correlation and implications for adjuvant therapy. Im J Radiat Oncol Biol Phys 8:1-11, 1982
28. Wilke H, Preusser P, Fink U, et al: Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: A phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 7:1318, 1989
29. Verschueren R, Willemse P, Sleijfer D, et al: Combined chemotherapeutic-surgical approach of locally advanced gastric cancer. Proc Am Soc Clin Oncol 7:93, 1988 (abstr 355)
30. Sinclair WK, Morton RA: X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 29:450-474, 1966
31. Choy H, Rodriguez FF, Koester S, et al: Investigation of Taxol as a potential radiation sensitizer. Cancer 71:3774-3778, 1993
32. Tepper JE: Combined radiotherapy and chemotherapy in the treatment of gastrointestinal malignancies. Semin Oncol 19:96-101, 1992
33. Choy H, Safran H: Preliminary analysis of a phase II study of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Semin Oncol 22:70-75, 1995
34. Akerley W, Choy H, Glantz M, et al: Weekly paclitaxel for metastatic non-small cell lung cancer (NSCLC): A phase I trial. Proc Am Soc Clin Oncol 15:377, 1996 (abstr 1122)
35. Blackstoch AW, Cox AD, Tepper JE: Treatment of pancreatic cancer: Current limitations, future possibilities. ONCOLOGY 10:301-307, 1996
36. Moore M, Anderson J, Burris H, et al: A randomized trial of gemcidine (GEM) versus 5-FU as a first-line therapy in advanced pancreatic cancer. Proc Am Soc Clin Oncol 14:199, 1995 (abstr 473)
37. Chang YF, Li LL, Wu CW, et al: Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 77:14-18, 1996
38. Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT); the Eastern Cooperative Oncology Group (ECOG) results. Proc Am Soc Clin Oncol 12:194, 1993 (abstr 566)
39. Ajani JA, Ilson K, Daugherty K, et al: Paclitaxel is active against carcinoma of the esophagus: Report of a phase II trial. Proc Am Soc Clin Oncol 13:192, 1994 (abstr 555)
40. Neugut AI, Hayek M, Howe G: Epidemiology of gastric cancer. Semin Oncol 23:281-291, 1996